Docetaxel plus ritonavir - Modra Pharmaceuticals

Drug Profile

Docetaxel plus ritonavir - Modra Pharmaceuticals

Alternative Names: ModraDoc 006; ModraDoc 006/r; ModraDoc001; ModraDoc003

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Modra Pharmaceuticals
  • Developer Modra Pharmaceuticals; Netherlands Cancer Institute
  • Class Amides; Antineoplastics; Carbamates; Small molecules; Taxanes; Thiazoles
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; Mitosis inhibitors; P-glycoprotein inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer; Solid tumours

Most Recent Events

  • 15 Nov 2017 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours released by Modra Pharmaceuticals ,
  • 03 Aug 2017 Chemical structure information added
  • 22 Jun 2017 Modra Pharmaceuticas has patent protection for Modulated Oral Drug Absorption technology worldwide (Modra Pharmaceuticals website, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top